{"entity":{"id":"nct06131450","kind":"trial","name":"A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies","aka":[],"tldr":"A phase 1/2 trial of BL-M07D1 in advanced solid tumours, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","summary":"A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies is a phase 1/2 interventional study registered as NCT06131450 by Sichuan Baili Pharmaceutical Co., Ltd., with 138 participants planned, started 2024-02-29 and due to reach its primary completion in 2026-12. Interventions recorded: BL-M07D1.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06131450","url":"https://clinicaltrials.gov/study/NCT06131450"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["systimmune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06131450","phase":"1/2","setting":"A Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 for Injection in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","enrolled":138,"outcomes":[]},"route":"/trials/nct06131450/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/"}]}}